| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6200721 | Ophthalmology | 2015 | 9 Pages |
Abstract
The BCVA gain achieved in the initial 6-month treatment period was maintained with an additional 12 months of bimonthly ranibizumab PRN treatment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ian FRCOphth, Sanjiv FRCS(Ed), PhD, Ben J.L. FRCOphth, Usha MD, PhD, Louise MBChB, PhD, Richard P. MBChB, MRCOphth, Jonathan MD, Sergio MD, Jignesh MD, Sobha FRCS, Chris CStat, Christopher MRCOphth, James MBBS, MRCP,